NVCR +67% on positive data from combination therapy.
STDY +36% on favorable patent ruling.
APOP +15% on grant of patent notice in EU.
DVAX +13% on PDUFA date for HEPLISAV-B remains unchanged.
INFI +11% on updates of Phase 1 data for IPI-549 at the AACR 2017.
IDXG +10% on European Patent Approval For Underlying Technology of its ThyraMIR microRNA Classifier.
ONCS +9% on Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response.
ARTX +8% on receiving a sole source follow-on contract to support the U.S. Army’s Virtual Clearance Training Suite program.
EBIO +7% on new preclinical data.
BCRX +6% on receiving approval for Mundesine in Japan.
ELOS +5% on acquisition by funds advised by Apax Partners for $11 per share in cash.
KITE +5% ongoing response rate in plenary session from its pivotal CAR-T trial.